Cosmos Health operates as a diversified, vertically integrated global healthcare group with activities in pharmaceutical distribution, contract manufacturing, and its own nutraceutical brands. Its quarterly updates give a clear view of whether growth plans are leading to better profitability and a stronger financial position. The third quarter 2026 numbers matter especially after a stretch of fast revenue growth paired with ongoing net losses, so the focus falls on margin trends and debt reduction. With new efforts underway in U.S. direct-to-consumer subscriptions and expanded contract manufacturing, this report helps show if operations are building a more solid base.
For the period ended September 30, 2026, COSM posted revenue of $16.68 million, down 2.5% from $17.11 million a year earlier and just under the $17.34 million consensus. Over nine months, revenue hit a record $53.6 million, an 18% rise from $45.57 million in the prior-year stretch.
Gross profit came in at $2.10 million, lifting the gross margin to 12.6%—a 465-basis-point sequential gain. The net loss narrowed to $5.25 million from $5.35 million in the year-ago quarter. Adjusted EBITDA improved about 18% sequentially, and interest expense dropped by more than half year over year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Balance sheet progress was clear. Total debt fell 34% from year-end to $12.83 million, total liabilities declined 18% to $38.49 million, and stockholders' equity rose 21% to $22.33 million. Working capital improved to $2.34 million from $0.12 million at the close of 2025, helped by the early settlement of the full $8.0 million ATW convertible note.
After the November 18, 2026 release, media coverage noted that shares rose in pre-market trading, with attention on the margin rebound and balance sheet steps rather than the small revenue shortfall. The report came shortly after a 1-for-20 reverse stock split effective November 13, 2026, which provides added context for recent price moves.
Pre-report sentiment had been measured, given the stock’s drop over the past twelve months and the pattern of quarterly losses. The gross margin recovery and debt paydown drew positive notice, even as investors weigh near-term profitability against longer-term growth plans.
Several items will likely draw focus in coming quarters. The U.S. direct-to-consumer subscription business entered the fourth quarter with more than 12,500 active subscriptions and roughly $1.83 million in monthly recurring value, pointing to about $22 million annualized. Growth here will serve as a useful demand indicator.
Margin trends stay central. The 465-basis-point sequential gross margin lift points to a better product mix and operating gains, though keeping that momentum will hinge on contract manufacturing and branded products. The contract manufacturing pipeline reached a record above 32.7 million units, offering some visibility ahead.
Balance sheet strength remains key. Management has stressed deleveraging, and further debt cuts could ease interest costs and support a route to profitability. New automation at the CosmoFarm distribution unit may also boost capacity into 2027.
Additional signals include fresh equity research coverage from Noble Capital Markets with an Outperform rating and the restart of share repurchases. Tracking subscription growth, sustained margins, and ongoing debt reduction should highlight the main near-term drivers.
In my own work, I turn to Tickeron’s AI Screener when screening healthcare names like COSM against peers. It lets me quickly apply filters for fundamentals, technical patterns, and performance metrics, which helps surface ideas without spending hours on manual checks. The tool has become a regular part of how I compare opportunities across the sector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
COSM saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In 85 of the 93 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for COSM turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 39 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
COSM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COSM crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for COSM entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where COSM's RSI Indicator exited the oversold zone, 38 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for COSM moved above the 200-day moving average on November 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +18.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where COSM advanced for three days, in 192 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
COSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (14.423). P/E Ratio (-0.455) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.850) is also within normal values, averaging (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (4.260).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. COSM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COSM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalDistributors